Bayer enlists Schering-Plough's aid for U.S. marketing

Share this article:

The companies also committed to a co-marketing agreement for future promotion of Schering-Plough's cardiovascular product, Zetia, in Japan. In addition, Bayer HealthCare will build up a new U.S.-based global oncology business unit and refocus its U.S. organization on high-profit specialty and biotech products to form Bayer HealthCare's Specialty Pharmaceuticals business.

Bayer estimates that approximately 1,800 U.S.-based Bayer primary care sales and marketing positions will be impacted, either through transfer to Schering-Plough or through staff reductions.

Bayer's drug products will remain the property and legal responsibility of Bayer and continue to be sold under the Bayer brand names. The agreement covers only those Bayer products already approved, not those in development.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.